DexCom (NASDAQ:DXCM) PT Raised to $145.00 at Canaccord Genuity Group

DexCom (NASDAQ:DXCM) had its target price hoisted by research analysts at Canaccord Genuity Group from $144.00 to $145.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group’s target price would suggest a potential upside of 5.06% from the stock’s current price.

Several other research firms have also recently issued reports on DXCM. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Raymond James raised their price objective on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada started coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Finally, UBS Group increased their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $141.07.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $138.01 on Friday. The business’s fifty day moving average price is $130.98 and its two-hundred day moving average price is $118.02. The stock has a market cap of $54.66 billion, a PE ratio of 105.35, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. DexCom has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. On average, analysts forecast that DexCom will post 1.76 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of DexCom stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 2,624 shares of DexCom stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 189,375 shares of company stock worth $25,530,859. Corporate insiders own 0.41% of the company’s stock.

Institutional Investors Weigh In On DexCom

A number of hedge funds have recently made changes to their positions in DXCM. Stableford Capital II LLC raised its holdings in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after purchasing an additional 88 shares in the last quarter. D Orazio & Associates Inc. grew its position in DexCom by 0.8% during the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after purchasing an additional 93 shares in the last quarter. Gulf International Bank UK Ltd grew its position in DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after purchasing an additional 98 shares in the last quarter. Finally, Harbor Investment Advisory LLC grew its position in DexCom by 13.1% during the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.